CSIMarket
 
Cyclacel Pharmaceuticals Inc   (CYCC)
Other Ticker:  
 
 
Price: $2.7200 $-0.08 -2.857%
Day's High: $2.8 Week Perf: 0.18 %
Day's Low: $ 2.65 30 Day Perf: 28.3 %
Volume (M): 15 52 Wk High: $ 13.30
Volume (M$): $ 41 52 Wk Avg: $6.93
Open: $2.65 52 Wk Low: $2.00



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -25
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) 0

Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of innovative drugs to treat various types of cancers and other serious diseases. The company utilizes its expertise in cell cycle regulation and DNA damage response to develop targeted therapies. Cyclacel Pharmaceuticals aims to improve patient outcomes by developing novel drugs that address the unique biological pathways involved in the development and progression of cancer. The company's drug candidates are designed to inhibit abnormal cell division and promote cell death in cancer cells, while sparing normal healthy cells. Cyclacel Pharmaceuticals is dedicated to advancing its drug candidates through clinical trials with the ultimate goal of providing effective treatment options for patients in need.


   Company Address: 200 Connell Drive Berkeley Heights 7922 NJ
   Company Phone Number: 517-7330   Stock Exchange / Ticker: NASDAQ CYCC
   CYCC is expected to report next financial results on March 07, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

Cyclacel Pharmaceuticals Set to Showcase Innovative Cancer Medicines at the 2024 BIO CEO & Investor Conference

Published Tue, Feb 20 2024 2:15 PM UTC

In an exciting development, Cyclacel Pharmaceuticals, Inc., a renowned biopharmaceutical company specializing in cancer cell biology, has recently announced its participation in the prestigious 2024 BIO CEO & Investor Conference. Scheduled to take place at the esteemed New York Marriott Marquis on February 26-27, 2024, this conference presents a significant opportunity for C...

Shares

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering, Aims to Boost Research and Development

Published Fri, Dec 22 2023 2:15 PM UTC


BERKELEY HEIGHTS, N.J., Dec. 22, 2023 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company specializing in innovative cancer treatments, recently revealed its plans for a registered direct offering. The company has entered into a definitive agreement for the purchase and sale of 388,200 shares of its common...

Clinical Study

Fadraciclib: Cyclacel Pharmaceuticals' Potential Game-Changer in Targeted Cancer Treatment

Published Mon, Dec 18 2023 2:00 PM UTC



Cyclacel Pharmaceuticals, a renowned biopharmaceutical company, has recently released Phase 1 data for its experimental drug, Fadraciclib, which suggests significant efficacy against tumors with CDKN2A, CDKN2B, and MTAP deletions. The preliminary results demonstrated a notable decrease in CDKN2A, CDKN2B, and PRMT5 protein levels, indicating a potential breakthrough...

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc Announces Revenue of $0.016 Million, Paving the Way for an Investor Opportunity



Cyclacel Pharmaceuticals Inc, a renowned biopharmaceutical company, recently released its financial results for the third quarter of 2023. While the revenue figures may seem low at $0.016 million, it is crucial to understand the context behind this decline. Despite the net deficit of $-5.982 million, larger than the previous year, strategic factors and upcoming events indicate that Cyclacel Pharmaceuticals Inc may present a significant opportunity for investors.
Revenue Insights and Future Expectations
Cyclacel Pharmaceuticals Inc's third-quarter revenue of $0.016 million reflects a temporary setback. However, it is essential to note that pharmaceutical companies often face fluctuations in revenue due to various factors such as drug development timelines, regulatory approvals, and clinical trials. These figures do not accurately reflect the long-term growth potential and overall strength of the company.

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc Faces Financial Challenges with $0.373 Million Revenue and $-5.398 Million Net Deficit in Fiscal Year 2023

Cyclacel Pharmaceuticals Inc (CYCC) has recently reported its financial results for the fiscal time-frame closing June 30, 2023. Despite generating revenue of $0.373 million, the company experienced a net deficit of $-5.398 million, which exceeded the previous year's deficit of $-4.525 million. This discrepancy raises concerns for investors and presents challenges for the company moving forward.
Looking ahead, Cyclacel Pharmaceuticals Inc is expected to release its next financial earnings report on November 09, 2023. This announcement will be crucial in determining the company's trajectory and whether it can turn its financial situation around.






 

Cyclacel Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com